MKS Instruments MKSI 深 沪
已收盘 12-12 16:00:00 美东时间
155.77
-11.030
-6.61%
华盛通- 最 高165.89
- 今 开164.37
- 成交量 144.20万股
- 最 低 153.1201
- 昨 收 166.80
- 总市值 104.63亿
- 52周最高 170.37
- 市盈率 静 55.42
- 换手率 2.15%
- 52周最低 54.18
- 委 比 -41.80%
- 总股本 6716.95万
- 历史最高 195.26
- 量 比 1.77
- 振 幅 7.66%
- 历史最低 10.41
- 每 手 1
- 风险率 24.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Shares of broader chip stocks are trading lower amid a pullback in Broadcom, which has weighed on AI and tech stocks.
Shares of broader chip stocks are trading lower amid a pullback in Broadcom, wh...
12-12 23:34
Shares of companies within the broader tech sector are trading higher amid the overall market strength. The sector may be experiencing momentum in reaction to Dell's Q3 earnings and strong guidance.
Shares of companies within the broader tech sector are trading higher amid the ...
11-27 04:29
Shares of companies in the broader chip sector are trading higher, rebounding from recent weakness in tech stocks. Investors may also be awaiting NVIDIA's earnings report after the close.
Shares of companies in the broader chip sector are trading higher, rebounding f...
11-20 04:27
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Needham Maintains Buy on MKS, Raises Price Target to $170
Needham analyst James Ricchiuti maintains MKS (NASDAQ:MKSI) with a Buy and raises the price target from $136 to $170.
11-07 02:32
MKS Instruments shares are trading higher after the company beat Q3 estimates and issued Q4 guidance above expectations.
MKS Instruments shares are trading higher after the company beat Q3 estimates a...
11-06 06:04
美股盘后 | MKS Instruments涨10.78%
MKS Instruments将于2025年11月5日发布第三季度财报，预期每股收益1.83美元，营收9.66亿美元。公司上季度营收同比增9.7%，毛利润4.53亿美元，净利率6.37%，并宣布派发每股0.22美元季度股息。
11-06 05:45
